Recruiting PHASE2 INTERVENTIONAL 5-arm NCT06382155

A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

A Phase 2, Randomized, Controlled, Multicenter Study of Vosoritide in Children With Idiopathic Short Stature

Sponsor: BioMarin Pharmaceutical

Interventions Human Growth Hormone Placebo Vosoritide Injection

Updated 7 times since 2024 Last updated: Mar 12, 2026 Started: Oct 21, 2024 Primary completion: Jun 30, 2026 Completion: Dec 31, 2036

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Idiopathic Short Stature and is currently actively recruiting participants. BioMarin Pharmaceutical leads this study, which shows 7 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE2
Sep 2025 — Mar 2026 [monthly]

Recruiting PHASE2
Feb 2025 — Sep 2025 [monthly]

Recruiting PHASE2
Jan 2025 — Feb 2025 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Jan 2025 [monthly]

Not Yet Recruiting PHASE2

▶ Show 2 earlier versions

Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BioMarin Pharmaceutical

Data source: BioMarin Pharmaceutical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Angers, France , Ann Arbor, United States , Boise, United States , Buffalo, United States , California City, United States , Chapel Hill, United States , Cincinnati, United States , Columbia, United States , Columbus, United States , Dallas, United States and 33 more locations